Cargando…
Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092)
A 20-yr-old man with Proteus syndrome (PS) and somatic mosaicism of the AKT1 c.49G > A p.(E17K) variant had asymmetric overgrowth of the right frontal and facial bones, asymmetric spinal overgrowth with thoracolumbar scoliosis, dilatation of the inferior vena cava, testicular cystadenoma, bilater...
Autores principales: | Biesecker, Leslie G., Edwards, Matthew, O'Donnell, Sheridan, Doherty, Paula, MacDougall, Thomas, Tith, Kate, Kazakin, Julia, Schwartz, Brian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996520/ https://www.ncbi.nlm.nih.gov/pubmed/32014856 http://dx.doi.org/10.1101/mcs.a004549 |
Ejemplares similares
-
Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania
por: Nandan, Devki, et al.
Publicado: (2018) -
Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome
por: Lindhurst, Marjorie J., et al.
Publicado: (2015) -
Case report: five-year experience of AKT inhibition with miransertib (MK-7075) in an individual with Proteus syndrome
por: Ours, Christopher A., et al.
Publicado: (2021) -
In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor
por: Yu, Yi, et al.
Publicado: (2017) -
In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy
por: Wang, Jianxun, et al.
Publicado: (2017)